class_family,name,IC_50_enter_mean,IC_50_enter_std,IC_50_enter_virus,IC_50_enter_host,IC_50_enter_ref,IC_50_cell_mean,IC_50_cell_std,IC_50_cell_efector,IC_50_cell_virus,IC_50_cell_target,IC_50_cell_ref,sequence,length,type,comment,vida_media_value,vida_media_host,vida_media_ref,mutations,ref_mutations,clinical_phase,comercial_name
F1,HP23,0.19,0.01,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,EMTWEEWEKKIEEYTKKIEEILK,23,Análogo CHR HIV-1,,,,,I37T; V38A; Q40H,Xiong (2017),,
F1,YIK,0.275,0.03,HIV-1 IIIB (NL4-3),MT-2,Su (2019),1.12 nM,1.12 nM,H9,HIV-1 IIIB,MT-2,Su (2019),EMTWEEWEKKIEEYIKKIEEILKKSQNQQIDL,32,Análogo CHR HIV-1,,1.3,ICR female mice,Su (2019),,,,
F1,HP23-E6-IDL,0.338,0.025,HIV-1 IIIB (NL4-3),MT-2,Su (2019),1.14 nM,1.14 nM,H9,HIV-1 IIIB,MT-2,Su (2019),EMTWEEWEKKIEEYTKKIEEILKKSQNQQIDL,32,Análogo CHR HIV-1,,1,ICR female mice,Su (2019),,,,
F1,HP23L,0.39,0.06,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,ELTWEEWEKKIEEYTKKIEEILK,23,Análogo CHR HIV-1,,,,,,,,
F1,SC35EK,0.39,0.11,HIV-1 NL4-3,MAGI,Otaka (2002),,,,,,,WEEWDKKIEEYTKKIEELIKKSEEQQKKNEEELKK ,35,Análogo CHR HIV-1,,,,,,,,
F1,V2o,0.42,0.15,HIV-1 HXB2,PM1 human T cell,Brauer (2013),,,,,,,WQTWERQVDNITQTISKALEEAQIQNEKNMYELQKLNQWDIFSNWF,46,Análogo CHR HIV-1,H-; -OH,,,,,,,
F1,MT-SC29,0.43,0.16,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWEEWDKKIEEYTKKIEELIKKSEEQQKKN,31,Análogo CHR HIV-1,,,,,,,,
F1,MT-C34,0.5,0.07,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,36,Análogo CHR HIV-1,,,,,Q40H; V38M; I37T,Chong (2012)(JBC),,
F1,2P23L,0.59,0.08,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,ELTWEEWEKKVEELEKKIEELLK,23,Análogo CHR HIV-1/2,,,,,,,,
F1,MT-WQ-IDL,0.6,0.1,HIV-1 IIIB,MT-2 ,Su (2016),1.2+-0.2 nM,1.2+-0.2 nM,H9,HIV-1 IIIB,MT-2,Su (2016),MTWEEWDKKIEEYTKKIEELIKKSQNQQIDL ,31,Análogo CHR HIV-1,,,,,V38A; A6V; Q79E; Q66R,Su (2016),,
F1,2P23,0.69,0.15,HIV-1 NL4-3,TZM-bl,Xiong (2017),0.24 nM,0.24 nM,293T,HIV-1NL4-3,U87-CXCR4 ,Xiong (2017),EMTWEEWEKKVEELEKKIEELLK,23,Análogo CHR HIV-1/2,,,,,E49K/A; L57R; E136G; N126K,Xiong (2017); Wu (2018),-,-
F1,SC29EK,0.7,0,HIV-1 NL4-3,TZM-bl,Chong (2014),2.5+-0.2 nM,2.5+-0.2 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Chong (2013),WEEWDKKIEEYTKKIEELIKKSEEQQKKN,29,Análogo CHR HIV-1,,,,,N43K; Q40H; I37T; V38A/M/E; E49A; Q39R,Chong (2014); Nishikawa (2008); Wu (2018),,
F1,MT-SC29EK,0.7,0,HIV-1 SG3 ΔEnv,TZM-bl,Chong (2014) (R),2.5+-0.2,2.5+-0.2,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Chong (2013)(FASEB),MTWEEWDKKIEEYTKKIEELIKKSEEQQKKN,31,Análogo CHR HIV-1,,,,,N43K; E49A; N126K; V38M,Wu (2018); Chong (2014)(R),,
F1,MT-SFT,0.8,0.1,HIV-1 NL4-3,TZM-bl,Chong (2014) (JBC),,,,,,,MTWETWEREIENYTRQIYRILEESQEQQDRNERDLLE ,37,Análogo CHR HIV-1,-,,,,Q56R; L33S; V38A/M; Q40H; N43K,Chong (2014),,
F1,MT-SC34_ROD,0.84,0.29,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWQEWEKQVRYLEANISKSLEQAQIQQEKNMYELQ,36,Análogo CHR HIV-2,,,,,,,,
F1,T2635,1.1,0.1,HIV-1 NL4-3,TZM-bl,Chong (2014),7 nM,7 nM,MT-2,HIV-1 IIIB,PBMC,Dwyer (2007),TTWEAWDRAIAEYAARIEALIRAAQEQQEKNEAALREL,38,Análogo CHR HIV-1,-,,,,N126K; K90E; A6V; K154Q; H28C,Yu (2014); Eggink (2011),,
F1,SC29,1.13,0.84,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,WEEWDKKIEEYTKKIEELIKKSEEQQKKN,29,Análogo CHR HIV-1,,,,,,,,
F1,MT-SC34_EHO,1.17,0.16,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWQQWERQVRFLDANITKLLEEAQIQQEKNMYELQ,36,Análogo CHR HIV-2,,,,,,,,
F1,AA-C34,1.3,0.1,HIV-1 NL4-3,TZM-bl,Chong (2012)(JBC),,,,,,,AAWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,36,Análogo CHR HIV-1,,,,,,,,
F1,MT-SC22,1.32,0.08,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWEEWDKKIEEYTKKIEELIKKS,24,Análogo CHR HIV-1,,,,,,,,
F1,MT-P3,1.38,0.32,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWQEWEQQVRYLEANISQRLEQAQIQQEKNMYELQ,36,Análogo CHR HIV-2/SIV,,,,,,,,
F1,2P23Q,1.39,0.45,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,EMTWQEWEQKVEELEKKIEELLK,23,Análogo CHR HIV-1/2,,,,,,,,
F1,Tifuvirtide/T1249,1.4,0.2,HIV-1 NL4-3,TZM-bl,Chong (2014),3 nM,3 nM,MT-2,HIV-1 IIIB,PBMC,Dwyer (2007),WQEWEQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF,39,Análogo CHR HIV-1,Ac-; -NH2,,,,V38E/R; L33S,Eggink (2008); Chinnadurai (2007),II,Tifuvirtide (Monogram Biosciences / Roche / Trimeris)
F1,FB006,1.4,,HIV-1 IIIB,H9,Zhang (2015)(IH),,,,,,,WEEMDREINNYTKLIHELIEESQNQQEKNEQELL,34,Análogo CHR HIV-1,,,,,,,,
F1,TM-C34,1.4,0.1,HIV-1 NL4-3,TZM-bl,Chong (2012)(JBC),,,,,,,TMWMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,36,Análogo CHR HIV-1,,,,,,,,
F1,SC34,1.4,0.7,HIV-1 NL4-3,PBMC,Nishikawa (2008),,,,,,,WMEWDRKIEEYTKKIKKLIEESQEQQEKNEKELK,34,Análogo CHR HIV-1,,,,,V38E; N43D,Nishikawa (2008),,
F1,SC34EK,1.6,0.2,HIV-1NL4-3,HeLa CD4/LTR-B-galactosidase,Naito (2009),,,,,,,WLEWDRKIEEYTKKIEELIKKSQEQQEKNEKELK ,34,Análogo CHR HIV-1,,,,,,,,
F1,WQ-IDL,1.6,0.1,HIV-1 IIIB,MT-2,Su (2016),5.6+-1.2 nM,5.6+-1.2 nM,H9,HIV-1 IIIB,MT-2,Su (2016),WEEWDKKIEEYTKKIEELIKKSQNQQIDL,29,Análogo CHR HIV-1,,,,,V38A; Q79E,Su (2016),,
F1,MT-SC22EK,1.7,0.2,HIV-1 SG3 ΔEnv,TZM-bl,Chong (2013)(FASEB),2.6+-0.2 nM,2.6+-0.2 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Chong (2013)(FASEB),MTWEEWDKKIEEYTKKIEELIKKS,22,Análogo CHR HIV-1,,,,,,,,
F1,CP32M,1.8,0.2,HIV-1 NL4-3,TZM-bl,Chong (2014),4 nM,4 nM,H9 Calcein-AM-labeled,HIV-1 IIIB,MT-2,He (2008),VEWNEMTWMEWEREIENYTKLIYKILEESQEQ,32,Análogo CHR HIV-1,,,,,,,,
F1,C34_EHO,1.88,0.35,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,WQQWERQVRFLDANITKLLEEAQIQQEKNMYELQ,34,Análogo CHR HIV-1,,,,,,,,
F1,C46-EHO,1.9,0.6,HIV-1 HXB2,PM1 human T cell,Brauer (2013),,,,,,,WQQWERQVRFLDANITKLLEEAQIQQEKNMYELQELDKNASLWNWF,46,Análogo CHR HIV-1,,,,,,,,
F1,T1144,2.13,,HIV-1 IIIB,MT-2,Lu (2012),5.89 nM,5.89 nM,H9,HIV-1 IIIB,MT-2,Lu (2012),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALREL,38,Análogo CHR HIV-1,Ac-; -NH2,,,,,,,
F1,C34,2.7,0.1,HIV-1 NL4-3,TZM-bl,Chong (2014),8.20+-0.13 nM,8.20+-0.13 nM,H9,HIV-1 IIIB,MT-2,Lu (2007)(JBC),WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL,34,Análogo CHR HIV-1,Ac-; -NH2,,,,V38M/A/E; N43K/D; Q52R; N126K; Q64A/L; A67G/S; I37T/K; Q66R; Q40H,Nishikawa (2008); Yu (2014); Nameki (2005); Yu (2018); Lu (2015); Chong (2012),I,(PeptiPharma)
F1,MT-SC21EK,2.7,0.3,HIV-1 SG3 ΔEnv,TZM-bl,Chong (2013)(FASEB),5.9+-0.3 nM,5.9+-0.3 nM,HL2/4,HIV-1 HXB2/3gpt,TZM-bl,Chong (2013)(FASEB),MTWEEWDKKIEEYTKKIEELIKK,21,Análogo CHR HIV-1,,,,,,,,
F1,Sifuvirtide/SFT,2.87,0.36,HIV-1 NL4-3,TZM-bl,Liu (2010),7.53 nM,7.53 nM,H9,HIV-1 IIIB,MT-2,Pan (2009),SWETWEREIENYTRQIYRILEESQEQQDRNERDLLE,36,Análogo CHR HIV-1,H-; -OH,26+-7.9,Homo sapiens,He (2008) (JBC),I37T; V38A; Q41R/K; N43K; N126K; A47I; Q52R; Q40H,Liu (2010); Yu (2018); Chong (2014),III,Sifuvirtide (FusoGen Pharmaceuticals)
F1,CT105,2.88,,HIV-1 SC 422661.8 subt B,TZM-bl,Liu (2018),,,,,,,MTWCDWRDEIERYTKKIEELIRAAQEWQEKNEAALKEL,38,Análogo CHR HIV-1,,2.7,Sprague Dawley rat,Liu (2018),,,,
F1,MT-SC20EK,3,0.1,HIV-1 SG3 ΔEnv,TZM-bl,Chong (2013)(FASEB),6.5+-0.7 nM,6.5+-0.7 nM,HL2/5,HIV-1 HXB2/3gpt,TZM-bl,Chong (2013)(FASEB),MTWEEWDKKIEEYTKKIEELIK,20,Análogo CHR HIV-1,,,,,,,,
F1,WQ-LDI,3.6,0.2,HIV-1 IIIB,MT-2,Su (2016),7.2+-1.0 nM,7.2+-1.0 nM,H9,HIV-1 IIIB,MT-2,Su (2016),WEEWDKKIEEYTKKIEELIKKSQNQQLDI,29,Análogo CHR HIV-1,,,,,,,,
F1,WQ-LDL,3.7,1.1,HIV-1 IIIB,MT-2,Su (2016),6.4+-2.7 nM,6.4+-2.7 nM,H9,HIV-1 IIIB,MT-2,Su (2016),WEEWDKKIEEYTKKIEELIKKSQNQQLDL,29,Análogo CHR HIV-1,,,,,,,,
F1,WQ-IDI,3.7,0.3,HIV-1 IIIB,MT-2,Su (2016),6.4+-1.8 nM,6.4+-1.8 nM,H9,HIV-1 IIIB,MT-2,Su (2016),WEEWDKKIEEYTKKIEELIKKSQNQQIDI,29,Análogo CHR HIV-1,,,,,,,,
F1,CP621-652,4.55,0.33,HIV-1 NL4-3,MT-2 ,He (2008) (JoV),4.23+-0.35 nM,4.23+-0.35 nM,H9,HIV-1 IIIB,MT-2,He (2008) (JoV),QIWNNMTWMEWDREINNYTSLIHSLIEESQNQ,32,Análogo CHR HIV-1,,,,,,,,
F1,MT-SC19EK,4.8,0.3,HIV-1 SG3 ΔEnv,TZM-bl,Chong (2013)(FASEB),11.6+-0.5 nM,11.6+-0.5 nM,HL2/6,HIV-1 HXB2/3gpt,TZM-bl,Chong (2013)(FASEB),MTWEEWDKKIEEYTKKIEELI,19,Análogo CHR HIV-1,,,,,,,,
F1,C46,4.9,2.1,HIV-1 HXB2,PM1 human T cell,Brauer (2013),,,,,,,WQQWERQVRFLDANITKLLEEAQIQQEKNMYELQELDKWASLWNWF,46,Análogo CHR HIV-1,H-; -OH,,,,,,,
F1,C34_ROD,5.51,2.84,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,WQEWEKQVRYLEANISKSLEQAQIQQEKNMYELQ,34,Análogo CHR HIV-1,,,,,,,,
F1,P3,6.34,1.94,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,WQEWEQQVRYLEANISQRLEQAQIQQEKNMYELQ,34,Análogo CHR HIV-2,,,,,I37T; V38A/M; Q40H; N43K,Xiong (2017),,
F1,C36M4A,6.84,1.62,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),5.57+-1.35 nM,5.57+-1.35 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WMEWDREINNYTSLIHSLIEESQNQQEKNEQILLEL,36,Análogo CHR HIV-1,,,,,,,,
F1,C36M3A,8.62,2.82,HIV-1 NL4-3,MT-2 ,Zheng (2014),3.08+-1.44 nM ,3.08+-1.44 nM ,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014),WMEWDREINNYTSLIHSLIEESQNQQEKIEQELLEL,36,Análogo CHR HIV-1,,,,,,,,-
F1,MT-WQ,8.8,0.4,HIV-1 IIIB,MT-2,Su (2016),14.8+-2.8 nM,14.8+-2.8 nM,H9,HIV-1 IIIB,MT-2,Su (2016),MTWEEWDKKIEEYTKKIEELIKKSQNQQ,28,Análogo CHR HIV-1,,,,,,,,
F1,C36M4,15.9,6.45,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),5.02+-1.36 nM,5.02+-1.36 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WTEWDREINNYTSQIHSLIEESQNQQEKNEQILNEL,36,Análogo CHR HIV-1,,,,,,,,
F1,C36M2A,18.2,7.98,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),3.58+-2.14 nM,3.58+-2.14 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WMEWDREINNYTSLIHSLIEESQNIQEKNEQELLEL,36,Análogo CHR HIV-1,,,,,,,,
F1,C36M1A,18.5,0.45,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),6.59+-2.62 nM,6.59+-2.62 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WMEWDREINNYTSLIHSLIEELQNIQEKNEQELLEL,36,Análogo CHR HIV-1,,,,,,,,
F1,DP178/T20/Enfuvirtide/ENF,22.04,1.19,HIV-1 NL4-3,MT-2,He (2008) (JBC),28 nM,28 nM,H9 Calcein-AM-labeled,HIV-1 IIIB,MT-2,He (2008) (PNAS),YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,36,Análogo CHR HIV-1,,3.8±0.6 (1.57),Homo sapiens (Sprague Dawley rat),Drugbank,V38A/W/G/E/R/M; I37T/K; S138A; Q40H; N43D/S/K; Q41R/K; G36D/S; L33S/V,Chong (2013); Eggink (2008); Nameki (2009); Liu (2010); Greenberg (2004); Chinnadurai (2007); Eggink (2011),IV,Fuzeon (Roche)
F1,C36,24.9,4.49,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),3.92+-1.14 nM,3.92+-1.14 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL,36,Análogo CHR HIV-1,,,,,,,,
F1,C36M1,28.5,4.57,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),2.97+-1.66 nM,2.97+-1.66 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WTEWDREINNYTSQIHSLIEELQNQQEKNEQELNEL,36,Análogo CHR HIV-1,,,,,,,,
F1,C36M3,30.5,10.8,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),6.49+-3.11 nM,6.49+-3.11 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WTEWDREINNYTSQIHSLIEESQNQQEKLEQELNEL,36,Análogo CHR HIV-1,,,,,,,,
F1,C36M0,39.8,0.87,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),5.86+-3.24 nM,5.86+-3.24 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WTEWDREINNYTSQIHSLIEESQNQQEKNEQELNEL,36,Análogo CHR HIV-1,,,,,,,,
F1,C36M2,42,3.72,HIV-1 NL4-3 gp41_N36G,MT-2,Zheng (2014)(AIDS),7.00+-1.22 nM,7.00+-1.22 nM,HL2/3,HIV-1 HXB2/3gpt,TZM-bl,Zheng (2014)(AIDS),WTEWDREINNYTSQIHSLIEESQNIQEKNEQELNEL,36,Análogo CHR HIV-1,,,,,,,,
F1,SC22EK,51.3,5.4,HIV-1 NL4-3,TZM-bl,Chong (2014),,,,,,,WEEWDKKIEEYTKKIEELIKKS ,22,Análogo CHR HIV-1,,,,,,,,
F1,SC22,54.58,6.94,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,WEEWDKKIEEYTKKIEELIKKS,22,Análogo CHR HIV-1,,,,,,,,
F1,WQ,123.4,6.5,HIV-1 IIIB,MT-2,Su (2016),159.5+-9.5 nM,159.5+-9.5 nM,H9,HIV-1 IIIB,MT-2,Su (2016),WEEWDKKIEEYTKKIEELIKKSQNQQ,26,Análogo CHR HIV-1,,,,,V38A; A6V; Q66R; Q79E;,Su (2016),,
F1,P21_EHO,402.35,295.78,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWQQWERQVRFLDANITKLL,21,Análogo CHR HIV-2,,,,,,,,
F1,P21_P3,534.45,295.78,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWQEWEQQVRYLEANISQRL,21,Análogo CHR HIV-2/SIV,,,,,,,,
F1,P21_ROD,571.8,41.3,HIV-1 NL4-3,TZM-bl,Xiong (2017),,,,,,,MTWQEWEKQVRYLEANISKSL,21,Análogo CHR HIV-2,,,,,,,,
F1,T1144-C10,,,,,,16.8 nM,16.8 nM,H9,HIV-1 IIIB,MT-2,Shibo (2009),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRELDKWASLWNWF,48,Análogo CHR HIV-1,,,,,,,,
F2,N36Fd,99,99,HIV-1 IIIB,MT-2,Chen (2010)(JBC),77 nM,77 nM,H9,HIV-1 IIIB,MT-2,Chen (2010)(JBC),SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILGYIPEAPRDGQAYVRKDGEWVLLSTFL,63,Análogo NHR,,,,,,,,
F2,N28Fd,39,39,HIV-1 IIIB,MT-2,Chen (2010)(JBC),21 nM,21 nM,H9,HIV-1 IIIB,MT-2,Chen (2010)(JBC),IEAQQHLLQLTVWGIKQLQARILAVERYGYIPEAPRDGQAYVRKDGEWVLLSTFL,55,Análogo NHR,,,,,,,,
F2,N36,2000,800,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),16400+-1800 nM,16400+-1800 nM,B-SC-1,HIV-1 LAV,NIH-3T3,Louis (2001),SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,36,Análogo NHR,,,,,,,,
F2,IZN17,22,11,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,IKKEIEAIKKEQEAIKKKIEAIEKLLQLTVWGIKQLQARIL,41,Análogo NHR,,,,,,,,
F2,IQN17,190000,30000,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,LKKELEALKKEQEALKKKLEALEKLLQLTVWGIKOLQARIL,41,Análogo NHR,,,,,,,,
F2,IQN23,15,7,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL,48,Análogo NHR,,,,,,,,
F2,IQN36,88,35,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,62,Análogo NHR,,,,,,,,
F2,IZN23,2.33,,HIV-1 HXB2,P4–2/R5,Carella (2005),,,,,,,IKKEIEAIKKEQEAIKKKIEAIEKEIEAQQHLLQLTVWGIKQLQARIL,48,Análogo NHR,,,,,,,,
F2,IZN36,26,7,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,IKKEIEAIKKEQEAIKKKIEAIEKEISGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARIL,62,Análogo NHR,,,,,,,,
F2,N17,13000,4000,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,LLQLTVWGIKQLQARIL,17,Análogo NHR,,,,,,,,
F2,N23,29000,10000,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,IEAQQHLLQLTVWGIKQLQARIL,23,Análogo NHR,,,,,,,,
F2,IIN17,140,50,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,RMKQIEDKIEEIESKIKKIENEIARIKKLLQLTVWGIKQLQARIL,45,Análogo NHR,,,,,,,,
F2,IQ_22N17,1400,300,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,KIEEIESKQKKIENEIARIKKLLQLTVWGIKQLQARIL,38,Análogo NHR,,,,,,,,
F2,II_22N17,160,10,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,KIEEIESKIKKIENEIARIKKLLQLTVWGIKQLQARIL,38,Análogo NHR,,,,,,,,
F2,IQ_15N17,5500,1500,HIV-1 HXB2,HOS-CD4/fusion,Eckert (2002),,,,,,,KQKKIENEIARIKKLLQLTVWGIKQLQARIL,31,Análogo NHR,,,,,,,,
F2,N17IZ,799.94,,HIV-1 HXB2,P4–2/R5,Carella (2005),,,,,,,LLQLTVWGIKQLQARILAIKKEIEAIKKEQEAIKKKIEAI,40,Análogo NHR,,,,,,,,
F2,N^36(e.g),,,,,,308+-22 nM,308+-22 nM,B-SC-1,vCBYF1-fusin,B-SC-1,Bewley (2002),SGIDQEQNNLTRLIEAQIHELQLTQWKIKQLLARIL,36,Análogo NHR,,,,,,,,
F3,PBD-3HR-LBD,,,,,,4.76+-0.31 ug/mL ,4.76+-0.31 ug/mL ,H9,HIV-1 IIIB,CD4+ MT-2,Qi (2008) (JBC),WMEWDREIEEYTKKIEEYTKKIEEYTKKIWASLWNWF,37,Artificial,,,,,,,,
F3,AP1,86.25,,HIV-1 IIIB,MT-2,Zhu (2015),,,,,,,KKISEEQKKIQEEIKKILEESKKILEEIERDWEMW,35,Artificial,,,,,,,,
F3,AP3,3.06,,HIV-1 IIIB,MT-2,Zhu (2015),,,,,,,KKISEEQKKIQEEIKKILEESKKILEEIKKDWEEWTM,37,Artificial,,6.02,Sprague Dawley rat,Zhu (2015),,,,
F3,AP2,23.05,,HIV-1 IIIB,MT-2,Zhu (2015),2.6+-0.3,2.6+-0.3,n.r.,HIV-1 NL4/3,n.r.,Shi (2012),KKISEEQKKIQEEIKKILEESKKILEEIKKDWEEW,35,Artificial,,5.25,Sprague Dawley rat,Zhu (2015),,,,
F4,TLT10,,,,,,28.70+-2.42 nM,28.70+-2.42 nM,H9,HIV-1 IIIB,MT-2,Pan (2011),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRELGGGGSGGGGSYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,84,Bifuncional,Unión T20 y T1144,,,,,,,
F4,TLT15,,,,,,19.89+-1.63 nM,19.89+-1.63 nM,H9,HIV-1 IIIB,MT-2,Pan (2011),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRELGGGGSGGGGSGGGGSYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,89,Bifuncional,Unión T20 y T1144,,,,,,,
F4,TLT20,,,,,,11.71+-0.98 nM,11.71+-0.98 nM,H9,HIV-1 IIIB,MT-2,Pan (2011),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRELGGGGSSGGGSGGGGSGGGGSYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,94,Bifuncional,Unión T20 y T1144,,,,,,,
F4,TLT25,,,,,,10.74+-0.73 nM,10.74+-0.73 nM,H9,HIV-1 IIIB,MT-2,Pan (2011),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRELGGGGSGGGGSGGGGSGGGGSGGGGSYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,99,Bifuncional,Unión T20 y T1144,,,,,,,
F4,TLT30,,,,,,6.36+-1.33 nM,6.36+-1.33 nM,H9,HIV-1 IIIB,MT-2,Pan (2011),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRELGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,104,Bifuncional,Unión T20 y T1144,,,,,,,
F4,TLT40,,,,,,25.54+-3.78 nM,25.54+-3.78 nM,H9,HIV-1 IIIB,MT-2,Pan (2011),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRELGGGGSCGGGSGGGGSGGGGSGGGGSGGGGSSGSGSGGGGSYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,114,Bifuncional,Unión T20 y T1144,,,,,,,
F4,TLT35,11.06,3.12,HIV-1 IIIB,MT-2,Pan (2011),3.98±0.73,3.98±0.73,H9,HIV-1 IIIB,MT-2,Pan (2011),TTWEAWDRAIAEYAARIEALLRALQEQQEKNEAALRELGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,109,Bifuncional,Unión T20 y T1144,,,,,,-,-
F4,2DLT,5.64,,HIV-1 IIIB,MT-2,Lu (2012),19.03 nM,19.03 nM,H9,HIV-1 IIIB,MT-2,Lu (2012),KKVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASNTGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSLERLAAENKEQQEQLARLLAEIRAAYEAIARDWAEWTT,258,Bifuncional,Unión D1D2 con T1144,,,,,,,
F4,sCD4-FIT45,0.92,,HIV-1 HXB2,TZM-bl,Falkenhagen (2017),0.173 ug/mL,0.173 ug/mL,CHO-WT,HIV-1 HXB2,TZM-bl,Falkenhagen (2017),KVVLGKKGDTVELTCTASQKKSIQFHWKNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYICEVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQGGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASNTGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSGGGGSMEWDREINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF,264,Bifuncional,Unión D1D2 con T45,,,,,,,
F4,4HR-LBD-VIRIP,91,21,HIV-1 IIIB,MT-2,Jiang (2016),112+-32 nM,112+-32 nM,H9,HIV-1 IIIB,MT-2,Jiang (2016),EELAKKAEELAKKAEELAKKAEELAKKAWASLWNWFLEAIPMSIPPEVKFNKPFVF,56,Bifuncional,Unión 4HR-LBD-VIRIP,,,,,,,
F4,4HR-LBD,956,110,HIV-1 IIIB,MT-2,Jiang (2016),1356+-256,1356+-256,H9,HIV-1 IIIB,MT-2,Jiang (2016),EELAKKAEELAKKAEELAKKAEELAKKAWASLWNWF,36,Bifuncional,Unión 4HR-LBD,,,,,,,
F5,VIRIP,765,139,HIV-1 IIIB,MT-2,Jiang (2016),996+-126,996+-126,H9,HIV-1 IIIB,MT-2,Jiang (2016),LEAIPMSIPPEVKFNKPFVF,20,Unión a FP,,,,,-,,-,-
F5,VIR-576,,,,,,,,,,,,LEAIPCSIPPEFLFGKPFVFLEAIPCSIPPEFLFGKPFVF,40,Unión a FP,1S-S; H-; -OH,,,,-,,II,VIR-576 (VIRO Pharmaceuticals)
